Technical Analysis for STOK - Stoke Therapeutics, Inc.

Grade Last Price % Change Price Change
B 13.87 2.66% 0.36
STOK closed up 2.66 percent on Monday, July 1, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Oversold Stochastic Weakness 0.00%
Pocket Pivot Bullish Swing Setup 2.66%
Volume Surge Other 2.66%
Wide Bands Range Expansion 2.66%
Gapped Up Strength 2.66%
Oversold Stochastic Weakness 2.66%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High about 5 hours ago
Rose Above 50 DMA about 5 hours ago
Up 3% about 5 hours ago
Up 2% about 5 hours ago
Up 1% about 5 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Stoke Therapeutics is a biotechnology company that is pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50 percent of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. Stoke was launched with investments by Apple Tree Partners. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Precision Medicine Genetic Diseases Proteins Epigenetics Severe Genetic Diseases

Is STOK a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 17.58
52 Week Low 3.35
Average Volume 879,605
200-Day Moving Average 7.78
50-Day Moving Average 13.75
20-Day Moving Average 15.06
10-Day Moving Average 14.16
Average True Range 0.96
RSI (14) 46.52
ADX 26.11
+DI 22.61
-DI 24.32
Chandelier Exit (Long, 3 ATRs) 14.69
Chandelier Exit (Short, 3 ATRs) 15.65
Upper Bollinger Bands 17.49
Lower Bollinger Band 12.62
Percent B (%b) 0.26
BandWidth 32.38
MACD Line -0.14
MACD Signal Line 0.20
MACD Histogram -0.3419
Fundamentals Value
Market Cap 619.35 Million
Num Shares 44.7 Million
EPS -2.43
Price-to-Earnings (P/E) Ratio -5.71
Price-to-Sales 22.55
Price-to-Book 1.21
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.79
Resistance 3 (R3) 14.74 14.37 14.64
Resistance 2 (R2) 14.37 14.14 14.40 14.59
Resistance 1 (R1) 14.12 13.99 14.25 14.18 14.54
Pivot Point 13.76 13.76 13.82 13.78 13.76
Support 1 (S1) 13.51 13.52 13.63 13.56 13.20
Support 2 (S2) 13.14 13.37 13.17 13.15
Support 3 (S3) 12.89 13.14 13.10
Support 4 (S4) 12.95